ASX 200: Race Oncology Funds HARNESS Trial Start

Highlights

• Additional funding enables HARNESS trial initiation.

• Ethics authorisation is secured for the study pathway.

• Site activation and enrolment steps remain next.

Race Oncology has secured additional funding to initiate its HARNESS study of RC two two zero with osimertinib in lung cancer. With ethics authorisation secured, attention turns to site activation and enrolment milestones.

Race Oncology (ASX:RAC) has secured additional funding to support the initiation of its HARNESS trial, which will evaluate RC two two zero in combination with osimertinib in non small cell lung cancer. With funding now confirmed for the study, the board has approved trial initiation, shifting the near-term focus from capital readiness to operational execution. Ethics authorisation has already been obtained, and the next steps relate to institutional processes, site activation, and patient enrolment.

What has Race Oncology announced?

Race Oncology has confirmed the securing of additional capital through a placement to sophisticated shareholders, alongside funds associated with early option conversion activity and a commitment linked to management-held options. The combined funding package is intended to cover the planned HARNESS study, enabling the company to move into the initiation phase.

Entity-rich definition: private placement

A private placement is a capital raising method where new shares are issued to eligible investors, typically sophisticated or professional participants, under applicable listing and disclosure rules.

What is HARNESS and why does it matter?

HARNESS is a clinical study designed to assess RC two two zero in combination with osimertinib in non small cell lung cancer. Combination studies are often used to evaluate whether a new therapy can improve outcomes alongside an established standard treatment.

Entity-rich definition: Phase one trial

A Phase one trial is an early clinical study primarily designed to assess safety, tolerability, dosing and early signals of activity in humans.

Entity-rich definition: non small cell lung cancer

Non small cell lung cancer is a broad category of lung cancers that accounts for the majority of cases and is often treated using targeted therapies when specific mutations are present.

What is RC two two zero in this context?

RC two two zero is Race Oncology’s investigational therapy being assessed for potential clinical utility in cancer settings. As an investigational candidate, its development pathway depends on structured clinical evaluation, safety profiling, and evidence that supports further study.

Entity-rich definition: investigational therapy

An investigational therapy is a treatment candidate that is being studied in clinical trials and has not yet received broad regulatory approval for the intended use.

Why is ethics authorisation important?

Ethics authorisation indicates that a Human Research Ethics Committee has reviewed the study protocol to ensure it meets ethical and safety standards for human research. It is a foundational milestone in trial readiness, but it is not the final step before enrolment.

Entity-rich definition: ethics authorisation

Ethics authorisation is approval from a recognised committee that a clinical study protocol is ethically acceptable and meets participant protection requirements.

What needs to happen before enrolment?

Patient enrolment remains subject to final institutional processes and site activation. In practical terms, this typically includes:

• final site approvals and administrative readiness

• confirmation of operational capacity at participating health services

• activation steps that allow screening and recruitment to begin

Entity-rich definition: site activation

Site activation is the process where a trial site completes required approvals, contracts, training and operational set-up so patient screening and enrolment can begin.

What does the placement structure signal?

The announcement frames the placement as supported by existing sophisticated shareholders, and the issue pricing is presented as reflecting confidence, rather than being deeply discounted. In capital management terms, that positioning can be important because it shapes perceptions around shareholder support and funding resilience.

Entity-rich definition: capital runway

Capital runway refers to how long a company can fund planned operations and milestones with available cash before needing additional financing.

What should readers watch next?

With trial initiation approved and ethics authorisation secured, the near-term focus moves to operational milestones.

Practical watchpoints

• confirmation of site activation completion

• commencement of patient screening and enrolment

• early study updates focused on safety and feasibility

• clarity on timelines for subsequent trial stages